T

Theravance Biopharma
D

TBPH

9.81000
USD
0.22
(2.24%)
Market Open
Volume
3,041
EPS
1
Div Yield
-
P/E
-10
Market Cap
482,399,844
Related Instruments
    A
    ACOR
    -0.26810
    (-30.48%)
    0.61160 USD
    A
    ALKS
    -0.480
    (-1.61%)
    29.270 USD
    C
    CRBP
    -0.100
    (-0.77%)
    12.860 USD
    F
    FOLD
    0.00000
    (0.00%)
    9.81000 USD
    G
    GLPG
    0.270
    (1.01%)
    27.000 USD
    I
    INSM
    -0.620
    (-0.88%)
    69.820 USD
    P
    PTCT
    -0.895
    (-1.94%)
    45.305 USD
    S
    SAGE
    -0.14000
    (-2.50%)
    5.47000 USD
    S
    SRPT
    0.330
    (0.28%)
    119.300 USD
    More
News

Title: Theravance Biopharma

Sector: Healthcare
Industry: Biotechnology
Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to better meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).